mRNA: A Next-Generation Approach to CAR-T Cell Engineering
Advancing CAR-T development through transient, non-integrating mRNA technology for safer, faster, and scalable cell therapy solutions.
Talk to Our ExpertsmRNA in CAR-T Therapy
Traditional CAR-T cell engineering relies on viral transduction or plasmid DNA transfection for stable gene expression. These methods, while effective, carry risks such as:
- Potential insertional mutagenesis due to random genomic integration
- Prolonged expression leading to off-target cytotoxicity
- Complex production workflows involving viral vector manufacturing
In contrast, mRNA-based CAR-T engineering delivers the CAR construct directly to the cytoplasm for immediate translation, eliminating integration risks. This transient expression (typically 3–7 days) allows precise control over dose and exposure, enabling safe evaluation of novel CAR constructs and reduced toxicity, particularly for solid tumor targets.
Key Advantages of mRNA-Based CAR-T Platforms
| Attribute | mRNA-Based CAR-T | DNA / Viral Vector CAR-T |
|---|---|---|
| Integration Risk | None | Possible (insertional mutagenesis) |
| Expression Duration | Transient (hours–days) | Stable (weeks–months) |
| Safety Profile | High | Moderate |
| Manufacturing Workflow | Cell-free IVT process | Viral vector production |
| Development Speed | Rapid (days) | Extended (weeks–months) |
| Optimization Flexibility | High | Limited post-integration |
Our mRNA platform uses non-viral transfection methods like electroporation or lipid nanoparticles (LNPs), preserving T-cell viability and phenotype. Chemically modified mRNA (e.g., with 5mC or m1Ψ) enhances translation efficiency and minimizes innate immune activation, ensuring robust CAR expression.
Our mRNA CRO & CDMO Capabilities
As a leading mRNA-focused CRO and CDMO, Echo BioSystems provides end-to-end support for mRNA-based CAR-T and cell therapy development. Our services include:
- mRNA Design: Codon optimization for CAR and TCR constructs, tailored for high expression.
- In Vitro Transcription (IVT): High-yield IVT with modified nucleotides (e.g., 5mC, m1Ψ)
- Analytical Characterization: Comprehensive QC with over 70 assays, including LC-MS, electrophoresis, and stability testing.
Our integrated workflow ensures rapid turnaround, regulatory compliance, and high-quality mRNA for functional testing.
Comprehensive Quality Control
Every mRNA batch undergoes rigorous testing to meet stringent standards:
| Attribute | QC Assay | Specification |
|---|---|---|
| Identity | Sanger Sequencing | Matches Target Sequence |
| mRNA Length | Capillary Gel Electrophoresis | Target ±30% |
| Concentration | UV Spectrophotometry | Target ±5% |
| Capping Efficiency | LC-MS | ≥95% |
| Purity (A260/280) | UV Spectrophotometry | 1.8-2.2 |
| Endotoxin | Kinetic Chromogenic Assay | <5 EU/mg |
| Residual dsRNA | Dot Blot Assay | Undetectable |
Each batch includes a detailed Analytical Report or Certificate of Analysis.
Explore Our Analytical Capabilities